BACKGROUND: Self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) have been proven effective in improving hemoglobin A1c (HbA1c) and in reducing hypoglycemia in patients with type 1 diabetes mellitus (T1DM). It is not clear, however, if CGM provides further efficacy and safety benefits beyond SMBG in the management of T1DM. METHODS: MEDLINE (1966-November 2009), COCHRANE REGISTRY (all years), and EMBASE (1980-November 2009), and article bibliographies were searched for randomized controlled trials (RCTs) investigating the use of CGM in patients with T1DM, with clinical outcomes, including HbA1c and hypoglycemia and/or hyperglycemia. RESULTS: Fourteen RCTs met eligibility criteria [n = 1188 patients, 97.4% with T1DM, age 29.0 ± 14.3 years, diabetes duration 11.7 ± 7.0 years, and baseline HbA1c 8.3 ± 0.8% (mean ± standard deviation)]. Compared with SMBG, the use of CGM was associated with a greater reduction in HbA1c [-0.3% (confidence interval: 0.4, -0.2), p < .0001]. The number of hypoglycemic events was not significantly different between the CGM and SMBG groups (0.52 ± 0.52 versus 0.52 ± 0.63 events/day, p = .5), but duration of hypoglycemia was shorter for the CGM group (75 ± 39 versus 89 ± 19 min/day), with an incremental reduction of hypoglycemia duration of -15.2 min/day, p < .0001. Continuous glucose monitoring also resulted in a shorter duration of hyperglycemia than SMBG (172 ± 125 versus 217 ± 152 min/day, p = .04). CONCLUSIONS: The use of CGM is associated with improvement in metabolic control in T1DM, with significant short- and long-term reductions in HbA1c and reduction in the duration of periods of hypoglycemia and hyperglycemia versus SMBG.
BACKGROUND: Self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) have been proven effective in improving hemoglobin A1c (HbA1c) and in reducing hypoglycemia in patients with type 1 diabetes mellitus (T1DM). It is not clear, however, if CGM provides further efficacy and safety benefits beyond SMBG in the management of T1DM. METHODS: MEDLINE (1966-November 2009), COCHRANE REGISTRY (all years), and EMBASE (1980-November 2009), and article bibliographies were searched for randomized controlled trials (RCTs) investigating the use of CGM in patients with T1DM, with clinical outcomes, including HbA1c and hypoglycemia and/or hyperglycemia. RESULTS: Fourteen RCTs met eligibility criteria [n = 1188 patients, 97.4% with T1DM, age 29.0 ± 14.3 years, diabetes duration 11.7 ± 7.0 years, and baseline HbA1c 8.3 ± 0.8% (mean ± standard deviation)]. Compared with SMBG, the use of CGM was associated with a greater reduction in HbA1c [-0.3% (confidence interval: 0.4, -0.2), p < .0001]. The number of hypoglycemic events was not significantly different between the CGM and SMBG groups (0.52 ± 0.52 versus 0.52 ± 0.63 events/day, p = .5), but duration of hypoglycemia was shorter for the CGM group (75 ± 39 versus 89 ± 19 min/day), with an incremental reduction of hypoglycemia duration of -15.2 min/day, p < .0001. Continuous glucose monitoring also resulted in a shorter duration of hyperglycemia than SMBG (172 ± 125 versus 217 ± 152 min/day, p = .04). CONCLUSIONS: The use of CGM is associated with improvement in metabolic control in T1DM, with significant short- and long-term reductions in HbA1c and reduction in the duration of periods of hypoglycemia and hyperglycemia versus SMBG.
Authors: David C Klonoff; Bruce Buckingham; Jens S Christiansen; Victor M Montori; William V Tamborlane; Robert A Vigersky; Howard Wolpert Journal: J Clin Endocrinol Metab Date: 2011-10 Impact factor: 5.958
Authors: Patricia A Cleary; Trevor J Orchard; Saul Genuth; Nathan D Wong; Robert Detrano; Jye-Yu C Backlund; Bernard Zinman; Alan Jacobson; Wanjie Sun; John M Lachin; David M Nathan Journal: Diabetes Date: 2006-12 Impact factor: 9.461
Authors: M A O'Connell; S Donath; D N O'Neal; P G Colman; G R Ambler; T W Jones; E A Davis; F J Cameron Journal: Diabetologia Date: 2009-04-25 Impact factor: 10.122
Authors: Roy W Beck; Irl B Hirsch; Lori Laffel; William V Tamborlane; Bruce W Bode; Bruce Buckingham; Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart A Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing Journal: Diabetes Care Date: 2009-05-08 Impact factor: 19.112
Authors: Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Parmida Zarei; Aaron N Winn; Michael O'Grady; Elbert S Huang Journal: Med Decis Making Date: 2018-11 Impact factor: 2.583
Authors: David C Klonoff; Courtney Lias; Robert Vigersky; William Clarke; Joan Lee Parkes; David B Sacks; M Sue Kirkman; Boris Kovatchev Journal: J Diabetes Sci Technol Date: 2014-06-13
Authors: John R Petrie; Anne L Peters; Richard M Bergenstal; Reinhard W Holl; G Alexander Fleming; Lutz Heinemann Journal: Diabetologia Date: 2017-10-25 Impact factor: 10.122
Authors: Susana R Patton; Stephen A DeLurgio; Amanda Fridlington; Cyndy Cohoon; Angela L Turpin; Mark A Clements Journal: Diabetes Technol Ther Date: 2014-04-28 Impact factor: 6.118
Authors: Ana M Gómez; Guillermo E Umpierrez; Oscar M Muñoz; Felipe Herrera; Claudia Rubio; Pablo Aschner; Richard Buendia Journal: J Diabetes Sci Technol Date: 2015-08-31